$1.580
+0.095 (+6.04%)收盤時
- 最高
- 1.660
- 開盤
- 1.510
- 成交量加權均價
- 1.57
- 成交量
- 55.74K
- 市值
- —
- 最低
- 1.460
- 成交金額
- 87.32K
- 企業價值/稅息折舊攤銷前利潤(TTM)
- -2.85
BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol.
AI 分析 of BioHarvest Sciences Inc (BHST)
持有Bioharvest Sciences Inc (BHST) is currently not a strong buy due to its low RSI of 32.086, indicating oversold conditions, and a significant year-to-date change of -69.87%. However, the company has shown revenue growth of 8% year-over-year in Q1 2026, with a projected annual revenue guidance of $42 million to $48 million, suggesting potential for recovery. The main risk is the forward P/E of 153.846, indicating high valuation expectations despite ongoing losses.
估值指標
事件時間軸
資訊
2.005-27NASDAQ.COMBioHarvest (BHST) Q4 2025 Earnings Transcript
9.505-14seekingalphaBioHarvest Sciences Q1 2026 Earnings Call Insights
9.505-14seekingalphaBioHarvest Sciences Reports Q1 Financial Results
7.505-13Yahoo FinanceBioHarvest Advances CDMO Program to Stage 2 with $1.125M Agreement
5.004-29seekingalphaBioHarvest Sciences Leadership Transition
BHST 常見問題 —— 由 Alphio AI 解答
BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol. It operates in the Healthcare sector.
Bioharvest Sciences Inc (BHST) is currently not a strong buy due to its low RSI of 32.086, indicating oversold conditions, and a significant year-to-date change of -69.87%. However, the company has shown revenue growth of 8% year-over-year in Q1 2026, with a projected annual revenue guidance of $42 million to $48 million, suggesting potential for recovery. The main risk is the forward P/E of 153.846, indicating high valuation expectations despite ongoing losses.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。